- Home
- GOSS vs JLS Comparison
GOSS vs JLS Comparison
Compare GOSS & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOSS | JLS |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.7M | 98.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GOSS | JLS |
|---|---|---|
| Price | $0.39 | $18.49 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 8.7M | 13.8K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $17.45 |
| 52 Week High | $3.87 | $19.09 |
Technical Indicators
Market Signals| Indicator | GOSS | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 52.39 |
| Support Level | $0.33 | $18.24 |
| Resistance Level | $0.47 | $18.81 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 46.72 | 44.46 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.